Related Experiment Video

Updated: Sep 27, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40

Ahmi Ben-Yehudah1, Rami Aqeilan, Dana Robashkevich

  • 1Department of Cellular Biochemistry and Human Genetics, Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 13, 2003
PubMed
Abstract

Insights

A new human-based chimeric protein, GnRH-DFF40, effectively targets and induces apoptosis in adenocarcinoma cells. This promising therapy demonstrated reduced tumor weight in preclinical models, offering a potential treatment for adenocarcinomas.

Area of Science:

  • Oncology
  • Biotechnology
  • Molecular Biology

Background:

  • Gonadotropin-releasing hormone (GnRH)-based chimeric proteins show promise for targeted cancer therapy.
  • Adenocarcinomas are a significant group of human cancers requiring novel therapeutic strategies.

Purpose of the Study:

  • To construct and characterize a novel GnRH-based chimeric protein for treating human adenocarcinomas.
  • To evaluate the efficacy and mechanism of action of the new chimeric protein.

Main Methods:

  • Construction and in vitro characterization of the GnRH-DFF40 chimeric protein, incorporating the apoptotic DNase-DFF40 (DNA fragmentation factor).
  • Assessment of cellular death pathways, including DNA fragmentation, TUNEL assay, and mitochondrial/caspase activation.
  • In vivo evaluation of GnRH-DFF40 efficacy in colon adenocarcinoma xenografts in nude mice.

Main Results:

  • GnRH-DFF40 demonstrated in vitro DNase activity and specifically targeted and killed adenocarcinoma cells.
  • Cell death was confirmed to occur via apoptosis, evidenced by increased sub-G(1) population, DNA fragmentation, TUNEL positivity, and characteristic apoptotic morphology.
  • Mitochondrial involvement was indicated by cytochrome c depletion and activation of caspase-9 and caspase-3.
  • Preliminary in vivo studies showed a reduction in tumor weight in colon adenocarcinoma xenografts treated with GnRH-DFF40.

Conclusions:

  • GnRH-DFF40 is a fully human-based chimeric protein, potentially avoiding the toxicity and immunogenicity associated with non-human-based therapies.
  • The protein effectively induces apoptosis in adenocarcinoma cells through intrinsic mitochondrial pathways.
  • GnRH-DFF40 represents a promising candidate for the development of new treatments for adenocarcinomas.

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...